RCS - InnoMed Tech Ltd. - Corporate Update

Capgemini SEAnnouncement

08/12/2025 08:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251208:nRSH6215Ka&default-theme=true

RNS Number : 6215K  InnoMed Tech Ltd.  08 December 2025

Innomed Tech Ltd.
Corporate Update
 

Innomed Tech Ltd. (BC, Canada) (the "Company") is pleased to announce the
following corporate update.

 

Progress of listing on the TSX Venture Exchange (TSXV)

The Company's listing application has been conditionally accepted by TSX
Venture Exchange Inc. (the "Exchange"). The Exchange's conditional acceptance
is provided based on the Company meeting Initial Listing Requirements to be
listed as a Tier 2 Industrial Issuer, by March 2nd, 2026.  The Company is
working with the TSXV to address the outstanding matters and complete its
listing.

 

Formal Issue of Electronic Common Shares

The Company has completed the common share issue by Computershare to all
shareholders, excluding escrowed and restricted common shares. The Company
will advise shareholders of the possible trading date, subject to listing
approval by the TSXV.

 

Patents and Awards

Following the EU patent award and numerous other jurisdiction awards, the
Company will focus on pursuing the US patent application with Office
Freylinger Luxembourg. Patent protection in major markets protects the
Company's intellectual property and strengthens future distribution contracts.

 

PureFlowCath Catheter to Market Development

The Company is finalising the working protocols and arrangements with
Cambridge Consultants Limited that follow the US Federal Drug Authority
"Recommended Waterfall Medical Device Design Process to Market", as reviewed
by Clark Regulatory.

 

 

Mr. Robert Rhodes            rrhodes@innomedtec.com
(mailto:rrhodes@innomedtec.com)

 

WWW.Innomedtec.com (http://WWW.Innomedtec.com)

 

 

Innomed Tech Ltd.

The Company's first medical device development subsidiary, PureFlowCath, is
developing the PureFlowCath Catheter System to provide continuous irrigation
("CSCI) with the objective of reducing urinary tract infections commonly
associated with the use of a urinary catheter.

 

Catheter-associated urinary tract infection (CAUTI) is the most frequent
healthcare-associated infection  worldwide, accounting for up to 40% of all
hospital-acquired infections and resulting in over 13,000 deaths annually in
the United States alone, according to data from the Centres for Disease
Control and Prevention.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFSLSWAEISESE



            Copyright 2019 Regulatory News Service, all rights reserved